ADMA and oxidative stress may relate to the progression of renal disease: Rationale and design of the VIVALDI study

Vascular Medicine

Volumn 10, Issue SUPPL. 1, 2005, Pages

  Böger, Rainer H ^a   Schwedhelm, Edzard ^a   Maas, Renke ^a   Quispe Bravo, Sabine ^b   Skamira, Cord ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

8 iso prostaglandin F2 ; Endothelium; Nitric oxide; Risk marker; Telmisartan

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ARACHIDONIC ACID; IRBESARTAN; LOSARTAN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; TELMISARTAN; VALSARTAN; ANGIOTENSIN II; ISOPROSTANE DERIVATIVE;

AMINO ACID ANALYSIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; HUMAN; KIDNEY DISEASE; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM; BLOOD LEVEL; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; KIDNEY FAILURE; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; STUDY DESIGN; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ARGININE; BENZIMIDAZOLES; BENZOATES; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DINOPROST; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; KIDNEY FAILURE; MIDDLE AGED; MULTICENTER STUDIES; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES; VALINE;

EID: 31344472862     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x05vm608oa     Document Type: Article

References (55)

1. United States Renal Data System. Annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004. Retrieved 2 March, 2005, from: http://www.usrds.org
2. Lüscher TF. The endothelium. Target and promoter of hypertension? Hypertension 1990; 15: 482-85.
3. van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 2001; 52: 299-305.
4. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-78.
5. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22: 36-52.
6. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67.
7. Paolisso G, D'Amore A, Volpe C et al. Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients. Metabolism 1994; 43: 1426-29.
8. Sano T, Umeda F, Hashimoto T, Nawata H, Utsumi H. Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia 1998; 41: 1355-60.
9. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
10. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95.
11. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-75.
12. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-94.
13. Achan V, Broadhead M, Malaki M et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolised by dimethylarginine dimethylaminohydolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-59.
14. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-74.
15. Böger RH, Bode-Böger SM, Szuba A et al. ADMA: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998; 98: 1842-47.
16. Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-95.
17. Abbasi F, Asagmi T, Cooke JP et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-03.
18. Stühlinger MC, Abbasi F, Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-26.
19. Lin KY, Ito A, Asagami T et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
20. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-95.
21. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A 2002; 99: 13527-32.
22. Zoccali C, Bode-Böger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-17.
23. Valkonen VP, Paiva H, Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-28.
24. Asagami T, Abbasi F, Stühlinger M et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51: 843-46.
25. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002; 90: 974-82.
26. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G),N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15: 590-93.
27. Lu G, Meier KE, Jaffa AA, Rosenzweig SA, Egan BM. Oleic acid and angiotensin II induce a synergistic mitogenic response in vascular smooth muscle cells. Hypertension 1998; 31: 978-85.
28. Benndorf R, Böger RH, Ergün S, Wieland T. Angiotensin II type 2 receptor inhibits VEGF-induced migration and in vitro tube formation of human endothelial cells. Circ Res 2003; 93: 438-47.
29. Mollnau H, Wendt M, Szocs K et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90: E58-E65.
30. Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res 1999; 85: 23-28.
31. Warnholtz A, Nickenig G, Schulz E et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the reninangiotensin system. Circulation 1999; 99: 2027-33.
32. Rachmani R, Levi Z, Zadok BS, Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study. Clin Pharmacol Ther 2002; 72: 302-307.
33. von zur Mühlen B, Kahan T, Hagg A, Millgard J, Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001; 19: 1813-18.
34. Wassmann S, Hilgers S, Laufs U, Böhm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22: 1208-12.
35. Schwedhelm E, Maas R, Troost R, Böger RH. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 2003; 42: 437-59.
36. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25: 279-86.
37. Schwedhelm E, Bartling A, Lenzen H et al. Urinary 8-iso-prostaglandin F2a is a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109: 843-48.
38. Cracowski JL, Ormezzano O. Isoprostanes, emerging biomarkers and potential mediators in cardiovascular diseases. Eur Heart J 2004; 25: 1675-78.
39. Davi G, Ciabattoni G, Consoli A et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-29.
40. Devaraj S, Hirany SV, Burk RF, Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem 2001; 47: 1974-79.
41. Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 2002; 25: 537-41.
42. Feillet-Coudray C, Chone F, Michel F et al. Divergence in plasmatic and urinary isoprostane levels in type 2 diabetes. Clin Chim Acta 2002; 324: 25-30.
43. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004; 109: 1729-34.
44. Tsikas D. Handling of commercially available enzyme immunoassays for 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha, iPF2alpha-II, 15-F2t-IsoP) in clinical research and science: considerations from the analytical and review point of view, Clin Chim Acta 2004; 344: 215-17.
45. Schwedhelm E, Bartling A, Lenzen H et al. 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease - Response. Circulation 2004; 110: e49-e50.
46. Young IS. Oxidative stress and vascular disease: insights from isoprostane measurement. Clin Chem 2005; 51: 14-15.
47. Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003; 42: 491-96.
48. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-78.
49. Lewis EJ, Hunsicker LG, Clarke WR et al. for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
50. Brenner BW, Cooper ME, de Zeeuw D et al. for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001; 345: 861-69.
51. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-78.
52. Strippoli GFM, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828-38.
53. Böger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005; 10(suppl 1): S19-25.
54. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 2005; 10(suppl 1): S49-57.
55. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005; 10(suppl 1): S89-95.